¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cobra venom cofactor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    º¸Á¶ÀÎÀÚ
  • ristocetin cofactor
    ¸®½ºÅ似ƾº¸Á¶ÀÎÀÚ
  • snake venom
    ¹ìµ¶
  • venom
    µ¶
  • venom gland
    µ¶»ù, µ¶¼±
  • venom hemolysis
    ¹ìµ¶¿ëÇ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    º¸Á¶ÀÎÀÚ
  • venom
    µ¶¹°, ¹ìµ¶
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cobra
    ÄÚºê¶ó
  • cofactor
    º¸Á¶ÀÎÀÚ
  • cobra head sign
    ÄÚºê¶ó¸Ó¸®Â¡ÈÄ
  • ristocetin cofactor
    ¸®½ºÅ似ƾº¸Á¶ÀÎÀÚ
  • venom duct
    µ¶°ü
  • venom gland
    µ¶»ù
  • venom hemolysis
    ¹ìµ¶¿ëÇ÷
  • snake venom
    ¹ìµ¶
  • venom
    µ¶¹°, ¹ìµ¶
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Russells viper venom time
    ·¯¼¿¹ÙÀÌÆÛº£³ð½Ã°£
  • heparin cofactor II
    ÇìÆÄ¸°º¸Á¶ÀÎÀÚ II
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cobra venom
    ÄÚºê¶óµ¶.
  • cobra head sign
    ÄÚºê¶ó ¸Ó¸® ¡ÈÄ
  • cofactor
    º¸Á¶ÀÎÀÚ.
  • cofactor
    Á¶ÀÎÀÚ
  • heparin cofactor II
    ÇìÆÄ¸°º¸Á¶ÀÎÀÚ II
  • ristocetin cofactor
    ¸®½ºÅ似ƾº¸Á¶ÀÎÀÚ(¡­ÜÍð¾ì×í­)
  • snake venom
    ¹ìµ¶(¡­Ô¸).
  • snake venom
    ¹ìµ¶(¡­Ô¸)
  • venom duct
    µ¶°ü(Ըη).
  • venom fang
    µ¶¾Æ(Ô¸ä´).
  • venom hemolysis
    »çµ¶¿ëÇ÷(ÞïÔ¸éÁúì).
  • venom hemolysis
    »çµ¶¿ëÇ÷(ÞïÔ¸éÁúì).
  • venom poisoning
    »çµ¶Áßµ¶(ÞïÔ¸ñéÔ¸).
  • venom ³ª venenum
    µ¶¾×(Ô¸äû), µ¶¹°(Ô¸Úª).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • venom gland
    µ¶»ù
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • venom substrate
    »çµ¶(ÞïÔ¸) ±âÁú(Ðñòõ)
  • cofactor
    º¸(Á¶)ÀÎÀÚ(ÜÍ(ð¾)ì×í­)
  • cofactor-requiring mutant
    º¸(Á¶)ÀÎÀڿ䱸 º¯ÀÌü(ÜÍ(ð¾)ì×í­é©Ï´Ü¨ì¶ô÷)
  • contact activation cofactor
    "Á¢ÃËȰ¼º º¸ÀÎÀÚ(ïÈõºüÀàõÜÍì×í­), (ÔÒ) high molecular weight kininogen"
  • platelet cofactor I
    Ç÷¼ÒÆÇ(úìá³÷ù) º¸ÀÎÀÚ (ÜÍì×í­) I
  • platelet cofactor II
    Ç÷¼ÒÆÇ(úìá³÷ù) º¸ÀÎÀÚ(ÜÍì×í­) II
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cobra head sign
    ÄÚºê¶ó ¸Ó¸® ¡ÈÄ
  • venom
    µ¶¾×, µ¶¹°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CoVF cobra venom factor
CVF cardiovascular failure; central visual field; cervicovaginal fluid; cobra venom factor
CoF cobra factor; cofactor
COBRA Consolidated Omnibus Reconciliation Act
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CVF Cobra Venom Factor
CoF Cobra venom factor
CoVF Cobra venom factor
COBRA Consolidated Omnibus Budget Reconciliation Act of 1985
HCII Heparin Cofactor II
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bee venom
    ¹úµ¶
    ¹ú ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å°´Â ÁÖ¿ä ¾Ë·¹¸£±â¿ø. ¹ú ¾Ë·¹¸£±â¶õ ¹ú¿¡ ½î¿´À» ¶§ ¹ßÁõÇÏ´Â ±× µ¶¿¡ ´ëÇÑ Áï½ÃÇü °ú¹ÎÁõÀ» ¸»ÇÑ´Ù. Áõ»óÀº ¾Æ³ªÇʶô½Ã½º¿Í °°ÀÌ ½ÉÇÑ °ÍÀ̳ª µÎµå·¯±â¿Í °°ÀÌ ºñ±³Àû °æÇÑ °ÍµéÀÌ Æ÷ÇԵȴÙ. ¹ú µ¶¿¡ Æ÷ÇԵǾî ÀÖ´Â ÁÖ¿ä Ç׿ø ¹°Áú·Î¼­´Â mellitin,
  • cobra head sign
    ÄÚºê¶ó ¸Ó¸® ¡ÈÄ
  • ristocetin cofactor
    ¸®½ºÅ似ƾ º¸Á¶ ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
cobra venom cofactor <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase.
Registry number: EC 3.4.21.47
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cobra venom factor A component of cobra venom that renders C3 proactivator (properdin factor B) susceptible to factor D of the properdin system, leading to activation of C3 and other components of complement and lysis of unsensitised erythrocytes.
(05 Mar 2000)
direct lytic factor of cobra venom A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent.
Synonym: cobra toxin, direct lytic factor of cobra venom.
(05 Mar 2000)
molybdenum cofactor A complex of molybdenum and molybdopterin required for a number of enzymes. A deficiency of this cofactor will result in lower activities of sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase causing elevated levels of sulfite, thiosulfite, xanthine, etc.
(05 Mar 2000)
cofactor <biochemistry> Inorganic complement of an enzyme reaction, usually a metal ions.
See: coenzyme.
(18 Nov 1997)
platelet cofactor I A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
platelet cofactor II <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
heparin cofactor II <chemical> A sulfated plasma protein with the mw of approximately 66kda. The protein is an inhibitor of thrombin in plasma that is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.
Pharmacological action: serine proteinase inhibitors.
Chemical name: Heparin cofactor II
(12 Dec 1998)
cobra A genus of poisonous snakes of the subfamily elapinae of the family elapidae. There are six recognised species, all inhabiting africa except the asiatic (indian) cobra, naja naja. Some species "spit" their venom into the eyes of their "enemies". So-called spitting cobras show a high degree of accuracy in aiming for the eyes. The ringhals, the most highly specialised of the spitting cobras, is limited to southern africa. Its spray destroys eye tissue and can cause blindness; its bite can cause death. (moore: poisonous snakes of the world, 1980, p80)
(12 Dec 1998)
cobra neurotoxins Toxins, contained in cobra (naja) venom that block cholinergic receptors; two specific proteins have been described, the small (short, type I) and the large (long, type II) which also exist in other elapid venoms.
(12 Dec 1998)
cobra toxin A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent.
Synonym: cobra toxin, direct lytic factor of cobra venom.
(05 Mar 2000)
cobra venoms Venoms from snakes of the genus naja (family elapidae). They contain many specific proteins that have cytotoxic, haemolytic, neurotoxic, and other properties. Like other elapid venoms, they are rich in enzymes. They include cobramines and cobralysins.
(12 Dec 1998)
black widow spider venom Potent neurotoxin that induces catastrophic release of acetylcholine from presynaptic terminals of cholinergic chemical synapses.
(18 Nov 1997)
venom <chemical> A toxic secretion in animals that is actively delivered to the target organism, either to paralyse or incapacitate or else to cause pain as a defence mechanism. Commonly include protein and peptide toxins.
(12 Jan 1998)
venom haemolysis That caused by haemolytic material in the venom of various species of snakes or other venomous animals.
(05 Mar 2000)
Russell's viper venom A venom used as a coagulant in the arrest of haemorrhage from accessible sites in haemophilia.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    °øµ¿ ÀÎÀÚ;º¸Á¶ ¿äÀÎ;°øÅë ÀÎÀÚ;¿©Àμö(ÀÎÀÚ)
  • venom
    µ¶
  • venom
    (¹ì,°Å¹Ì µûÀ§ÀÇ)µ¶;¾ÇÀÇ;¿øÇÑ;µ¶¼³
  • cobra
    ÄÚºê¶ó
  • cobra (del capello)
    ÄÚºê¶ó(Àεµ.¾ÆÇÁ¸®Ä«»ê µ¶»ç)
  • king cobra
    Å·ÄÚºê¶ó(µ¿³²¾Æ»êÀÇ Å« µ¶»ç)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á